Get the Stockscreener App
23.30
8.22%
1.77
After Hours:
23.21
-0.09
-0.39%
Neurogene Inc stock is traded at $23.30, with a volume of 1.02M.
It is up +8.22% in the last 24 hours and up +0.78% over the past month.
Neurogene Inc is a clinical stage biotechnology company whose objective is to harness the power of gene therapy which is combined with its EXACT gene regulation technology to turn today's complex devastating neurological diseases into treatable conditions.
See More
Previous Close:
$21.53
Open:
$21.51
24h Volume:
1.02M
Relative Volume:
2.40
Market Cap:
$346.12M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+50.03%
1M Performance:
+0.78%
6M Performance:
-38.47%
1Y Performance:
-27.19%
1-Day Range:
$20.96
$26.48
1-Week Range:
$15.16
$26.48
52-Week Range:
$14.42
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Name
Neurogene Inc
Sector
Industry
Phone
(877) 237-5020
Address
535 W 24TH STREET, NEW YORK
Compare NGNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
23.30 | 346.12M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-29-24 | Initiated | Leerink Partners | Outperform |
| Mar-21-24 | Initiated | William Blair | Outperform |
| Jan-08-24 | Initiated | H.C. Wainwright | Buy |
| Jan-05-24 | Initiated | Stifel | Buy |
| Jan-04-24 | Initiated | TD Cowen | Outperform |
View All
Neurogene Inc Stock (NGNE) Latest News
Neurogene Inc [NASDAQ: NGNE] Sees Increase in Stock Value - Knox Daily
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Neurogene Inc (NGNE) Stock: A Year of Stock Market Dynamics - The InvestChronicle
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc.NGNE - PR Newswire
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Buy” from Brokerages - Defense World
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - Victoria Advocate
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Neurogene Inc. (NGNE) Investors to Inquire about Securities Investigation - ACCESS Newswire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Barclays PLC Purchases 11,316 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Highlights Progress in Rett Syndrome Program - TipRanks
Jane Street Group LLC Invests $324,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Neurogene Inc. (NASDAQ:NGNE) Receives $60.83 Average PT from Analysts - MarketBeat
7,050 Shares in Neurogene Inc. (NASDAQ:NGNE) Purchased by Franklin Resources Inc. - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Sells 1,463 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Acquires 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
State Street Corp Buys 36,687 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
BNP Paribas Financial Markets Purchases 1,429 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Charles Schwab Investment Management Inc. Buys 741 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks By Investing.com - Investing.com South Africa
Neurogene's SWOT analysis: gene therapy stock shows promise amid risks - Investing.com
The Next Frontier in Neurological Treatment? Neurogene Inc's Bold Vision! - Jomfruland.net
Short Interest in Neurogene Inc. (NASDAQ:NGNE) Drops By 28.7% - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
COMMODORE CAPITAL LP Acquires 600,000 Shares in Neurogene Inc - GuruFocus.com
MetLife Investment Management LLC Invests $254,000 in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene Inc. (NASDAQ:NGNE) Shares Bought by Fmr LLC - MarketBeat
Neurogene Inc. (NASDAQ:NGNE) Shares Sold by Janus Henderson Group PLC - MarketBeat
Neurogene and Ventyx Biosciences rises after insider buying by executives - MSN
RTW Investments LP Buys 64,691 Shares of Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Redmile Group LLC Has $40.46 Million Position in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Walleye Capital LLC Cuts Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - MarketBeat
Insider SignalsDec 3 - substack.com
Neurogene files to sell 4M shares of common stock for holders - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Neurogene Inc. (NGNE) And Encourages Shareholders to Reach Out - AccessWire
Neurogene Inc. sees significant stock purchases by Samsara BioCapital - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Neurogene Inc. (NGNE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Neurogene Inc. (NGNE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
CEO Rachel Mcminn Increases Stake in Neurogene Inc with Recent S - GuruFocus.com
Neurogene retains stock target, buy rating amid Rett syndrome trial data - Investing.com Canada
Insider Buying: Christine Cvijic Acquires 24,000 Shares of Neuro - GuruFocus.com
Neurogene president buys $491,400 in company stock By Investing.com - Investing.com Nigeria
Neurogene CEO Rachel McMinn acquires $968,999 in stock By Investing.com - Investing.com Nigeria
Neurogene president buys $491,400 in company stock - Investing.com
Neurogene CEO Rachel McMinn acquires $968,999 in stock - Investing.com India
Neurogene Inc Stock (NGNE) Financials Data
There is no financial data for Neurogene Inc (NGNE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):